Literature DB >> 25267274

Ventricular tachyarrhythmia recurrence in primary versus secondary implantable cardioverter-defibrillator patients and role of electrophysiology study.

Sarah Zaman1, Gopal Sivagangabalan, William Chik, Wayne Stafford, John Hayes, Russell Denman, Glenn Young, Prashanthan Sanders, Pramesh Kovoor.   

Abstract

PURPOSE: In recent years, there has been a shift away from performing electrophysiologic study (EPS) to guide implantable cardioverter-defibrillator (ICD) implantation with a reliance on left ventricular ejection fraction (LVEF) alone.
METHODS: ICD patients were prospectively recruited from the multicentre COMFORT (Concept of Optimal Management of ventricular Fibrillation Or Very fast ventricular Tachycardia) trial. Primary prevention ICD patients (n = 260, groups 1 and 2) were compared to secondary prevention ICD patients (n = 210, group 3). Primary prevention ICDs were implanted in patients with ischemic cardiomyopathy based on LVEF ≤ 40 % and inducible ventricular tachycardia (VT) at EPS (n = 123, group 1) or impaired LVEF alone (LVEF ≤ 30 % or LVEF ≤ 35 % with NYHA class II or III; n = 137, group 2). EPS was performed in 61 % of secondary prevention ICD patients (n = 129). Patients were followed up for >12 months with a primary endpoint of spontaneous VT/ventricular fibrillation (VF).
RESULTS: A significantly higher rate of spontaneous VT/VF occurred in secondary versus primary prevention ICD patients (P < 0.001) and in EPS-guided versus LVEF-guided primary prevention ICD patients (P = 0.029). At 2 years, the proportion of patients with ≥1 VT/VF episode was 24.6 ± 4.2 %, 19.9 ± 4.6 % and 37.1 ± 3.9 % for groups 1, 2 and 3, respectively. In the secondary prevention, patients who underwent EPS, VT/VF occurred in 44.4 ± 5.9 % and 14.1 ± 6.6 % with a positive versus negative result, respectively (P = 0.02).
CONCLUSIONS: Secondary prevention ICD patients have more spontaneous VT/VF than primary prevention ICD patients. Secondary and primary prevention ICD patients with inducible VT at EPS have more VT/VF than patients without inducible VT or impaired LVEF alone.

Entities:  

Mesh:

Year:  2014        PMID: 25267274     DOI: 10.1007/s10840-014-9941-8

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  22 in total

1.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

2.  Long-term follow-up of primary and secondary prevention implantable cardioverter defibrillator patients.

Authors:  Guido H van Welsenes; Johannes B van Rees; C Jan Willem Borleffs; Suzanne C Cannegieter; Jeroen J Bax; Lieselot van Erven; Martin J Schalij
Journal:  Europace       Date:  2011-01-05       Impact factor: 5.214

3.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

4.  Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. Multicenter Automatic Defibrillator Implantation Trial Investigators.

Authors:  A J Moss; W J Hall; D S Cannom; J P Daubert; S L Higgins; H Klein; J H Levine; S Saksena; A L Waldo; D Wilber; M W Brown; M Heo
Journal:  N Engl J Med       Date:  1996-12-26       Impact factor: 91.245

5.  Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial.

Authors:  Michael O Sweeney; Mark S Wathen; Kent Volosin; Ismaile Abdalla; Paul J DeGroot; Mary F Otterness; Alice J Stark
Journal:  Circulation       Date:  2005-05-31       Impact factor: 29.690

6.  A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.

Authors: 
Journal:  N Engl J Med       Date:  1997-11-27       Impact factor: 91.245

7.  Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients.

Authors:  James P Daubert; Wojciech Zareba; W Jackson Hall; Claudio Schuger; Andrew Corsello; Angel R Leon; Mark L Andrews; Scott McNitt; David T Huang; Arthur J Moss
Journal:  J Am Coll Cardiol       Date:  2005-12-15       Impact factor: 24.094

8.  Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.

Authors:  Bruce L Wilkoff; Brian D Williamson; Richard S Stern; Stephen L Moore; Fei Lu; Sung W Lee; Ulrika M Birgersdotter-Green; Mark S Wathen; Isabelle C Van Gelder; Brooke M Heubner; Mark L Brown; Keith K Holloman
Journal:  J Am Coll Cardiol       Date:  2008-08-12       Impact factor: 24.094

9.  Long-term outcomes of inducible very fast ventricular tachycardia (cycle length 200-250 ms) in patients with ischemic cardiomyopathy.

Authors:  Saurabh Kumar; Gopal Sivagangabalan; Man-Chun Choi; Vicki Eipper; Aravinda Thiagalingam; Pramesh Kovoor
Journal:  J Cardiovasc Electrophysiol       Date:  2009-10-08

10.  Outcomes of early risk stratification and targeted implantable cardioverter-defibrillator implantation after ST-elevation myocardial infarction treated with primary percutaneous coronary intervention.

Authors:  Sarah Zaman; Gopal Sivagangabalan; Arun Narayan; Aravinda Thiagalingam; David L Ross; Pramesh Kovoor
Journal:  Circulation       Date:  2009-07-06       Impact factor: 29.690

View more
  4 in total

1.  Prognostic impact of recurrences of ventricular tachyarrhythmias and appropriate ICD therapies in a high-risk ICD population.

Authors:  Tobias Schupp; Ibrahim Akin; Linda Reiser; Armin Bollow; Gabriel Taton; Thomas Reichelt; Dominik Ellguth; Niko Engelke; Uzair Ansari; Kambis Mashayekhi; Christel Weiß; Christoph Nienaber; Muharrem Akin; Martin Borggrefe; Michael Behnes
Journal:  Clin Res Cardiol       Date:  2019-02-12       Impact factor: 5.460

2.  Left ventricle remodeling predicts the recurrence of ventricular tachyarrhythmias in implantable cardioverter defibrillator recipients for secondary prevention.

Authors:  Wei-Chieh Lee; Huang-Chung Chen; Yung-Lung Chen; Tzu-Hsien Tsai; Kuo-Li Pan; Yu-Sheng Lin; Mien-Cheng Chen
Journal:  BMC Cardiovasc Disord       Date:  2016-11-21       Impact factor: 2.298

3.  Risk of subsequent ventricular arrhythmia is higher in primary prevention patients with implantable cardioverter defibrillator than in secondary prevention patients.

Authors:  You Zhou; Shuang Zhao; Keping Chen; Wei Hua; Yangang Su; Silin Chen; Zhaoguang Liang; Wei Xu; Shu Zhang
Journal:  BMC Cardiovasc Disord       Date:  2019-10-21       Impact factor: 2.298

4.  Mortality Implications of Appropriate Implantable Cardioverter Defibrillator Therapy in Secondary Prevention Patients: Contrasting Mortality in Primary Prevention Patients From a Prospective Population-Based Registry.

Authors:  Fahad Almehmadi; Andreu Porta-Sánchez; Andrew C T Ha; Hadas D Fischer; Xuesong Wang; Peter C Austin; Douglas S Lee; Kumaraswamy Nanthakumar
Journal:  J Am Heart Assoc       Date:  2017-08-19       Impact factor: 5.501

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.